Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06220630
Other study ID # 2021[516]
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date August 1, 2021
Est. completion date December 31, 2025

Study information

Verified date January 2024
Source First Affiliated Hospital, Sun Yat-Sen University
Contact Yuxuan Gao, MD
Phone +86 18142846375
Email gaoyx9@mail2.sysu.edu.cn
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this observational study is to investigate the features in Chinese male breast cancer (MBC) patients. The main question it aims to answer is: - The characteristics, treatment patterns and prognosis of Chinese MBC patients. The clinicopathological characteristics, treatment information and follow-up data of participants will be extracted from a Chinese national database (Chinese Society of Clinical Oncology Breast Cancer database) and other involved Chinese centers. Researchers will investigate the features, survival associated factors and other relevant factors of this population.


Description:

The goal of this observational study is to investigate the features in Chinese male breast cancer (MBC) patients. The main question it aims to answer is: - The characteristics, treatment patterns and prognosis of Chinese MBC patients. The clinicopathological characteristics, treatment information and follow-up data of participants will be extracted from a Chinese national database (Chinese Society of Clinical Oncology Breast Cancer database) and other involved Chinese centers. Researchers will investigate the features, survival associated factors and other relevant factors of this population. The collected variables included: survival time, survival status, year of diagnosis, age, stage, molecular subtype statuses, histology, grade, and surgery, radiotherapy and systemic therapies utilization.


Recruitment information / eligibility

Status Recruiting
Enrollment 1200
Est. completion date December 31, 2025
Est. primary completion date August 1, 2025
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria: - Biological sex is male; - Microscopically diagnosed as primary breast cancer. Exclusion Criteria: - Presence of skin-origin malignancy on the breast.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Breast cancer
Male patients who were microscopically diagnosed as primary breast cancer.

Locations

Country Name City State
China First affiliated hospital of Sun Yat-sen university Guangzhou Guangdong

Sponsors (33)

Lead Sponsor Collaborator
First Affiliated Hospital, Sun Yat-Sen University Affiliated Sanming First Hospital of Fujian Medical University, Beijing 302 Hospital, Beijing Medical Award Foundation, First Affiliated Hospital Xi'an Jiaotong University, First Hospital of China Medical University, First People's Hospital of Foshan, Fujian Provincial Hospital, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangdong Provincial People's Hospital, Guangdong Women and Children Hospital, Jiangmen Central Hospital, Jieyang People's Hospital, Lianjiang Pepole's Hospital, Lianjiang, National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Peking University First Hospital, Peking University Shenzhen Hospital, Shantou Central Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Sun Yat-sen University, The Affiliated Cancer Hospital of Xinjiang Medical University, The Affiliated Cancer Hospital of Zhengzhou University, The Affiliated Hospital Of Guizhou Medical University, The Affiliated Hospital of Qingdao University, The First Affiliated Hospital with Nanjing Medical University, The First Affiliated Hospital, Zhejiang University, The Fourth Hospital of Hebei Medical University, The Second Affiliated Hospital of Harbin Medical University, The Second Affiliated Hospital, Guangzhou Medical University, The Third Affiliated Hospital of Kunming Medical University, The Third Hospital of Nanchang City, Zhanjiang Central Hospital, Zhuhai Hospital of Integrated Traditional Chinese and Western Medicine

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall survival The duration between the date of the first pathologic diagnosis and death from any cause or last follow-up. From the time of diagnosis to August 1, 2024 (anticipated).
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A